Cargando…

Regulatory T Cell Suppressive Activity Predicts Disease Relapse During Disease-Modifying Anti-rheumatic Drug Dose Reduction in Rheumatoid Arthritis: A Prospective Cohort Study

When the dose of conventional disease-modifying anti-rheumatic drugs (cDMARDs) is tapered in rheumatoid arthritis (RA) patients who achieve sustained remission, biomarkers for predicting disease relapse may be needed. A prospective, unblinded cohort study was conducted in nine RA patients with remis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kanjana, Korawit, Chevaisrakul, Parawee, Matangkasombut, Ponpan, Paisooksantivatana, Karan, Lumjiaktase, Putthapoom
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011614/ https://www.ncbi.nlm.nih.gov/pubmed/32118010 http://dx.doi.org/10.3389/fmed.2020.00025

Ejemplares similares

Inhibitory activity of FOXP3+ regulatory T cells reveals high specificity for displaying immune tolerance in remission state rheumatoid arthritis
por: Kanjana, Korawit, et al.
Publicado: (2020)

Hybrid and herd immunity 6 months after SARS-CoV-2 exposure among individuals from a community treatment program
por: Chevaisrakul, Parawee, et al.
Publicado: (2023)

Immunologic changes after house dust mite modified rush subcutaneous immunotherapy in allergic rhinitis children
por: Rattanamanee, Tipyapa, et al.
Publicado: (2022)

Quorum sensing triggers the stochastic escape of individual cells from Pseudomonas putida biofilms
por: Cárcamo-Oyarce, Gerardo, et al.
Publicado: (2015)

iNKT Cells and Their Potential Lipid Ligands during Viral Infection
por: Opasawatchai, Anunya, et al.
Publicado: (2015)

Unmasking the role of mast cells in dengue
por: Avirutnan, Panisadee, et al.
Publicado: (2013)

Gout, Rheumatism, and Rheumatoid Arthritis
Publicado: (1900)

Chronic Rheumatism and Rheumatoid Arthritis
por: Lindsay, J.
Publicado: (1908)

Rheumatic diseases, rheumatism and arthritis
por: Brugsch, Heinrich Georg, 1903-
Publicado: (1957)

Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis
por: Zhao, Sizheng Steven, et al.
Publicado: (2022)

Disease-modifying anti-rheumatic drugs improve the cardiovascular profile in patients with rheumatoid arthritis
por: Giachi, Andrea, et al.
Publicado: (2022)

Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
por: Das, Priyam, et al.
Publicado: (2023)

Decreased chronic kidney disease in rheumatoid arthritis in the era of biologic disease-modifying anti-rheumatic drugs
por: Hanaoka, Hironari, et al.
Publicado: (2022)

A Treatise on Rheumatism and Rheumatoid Arthritis
Publicado: (1892)

The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases
por: Chou, CT, et al.
Publicado: (2007)

Effect of Anti-Rheumatic Drugs on Cardiovascular Disease Events in Rheumatoid Arthritis
por: Baoqi, Yang, et al.
Publicado: (2022)

Reduction of peripheral regulatory T cells in active rheumatoid arthritis patients with coronary artery disease
por: Wang, Yanyan, et al.
Publicado: (2021)

Anti-rheumatic treatment is not associated with reduction of pentraxin 3 in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
por: Deyab, Gia, et al.
Publicado: (2017)

Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis
por: Choy, Ernest H
Publicado: (2019)

Exploring the treatment burden of disease-modifying anti-rheumatic drug monitoring in people with rheumatoid arthritis
por: Ryan, Sarah, et al.
Publicado: (2023)

Disease-modifying anti-rheumatic drugs associated with different diabetes risks in patients with rheumatoid arthritis
por: Su, Yu-Jih, et al.
Publicado: (2023)

Effect of Biological Disease-modifying Anti-rheumatic Drugs on Airway and Interstitial Lung Disease in Patients with Rheumatoid Arthritis
por: Kurata, Izumi, et al.
Publicado: (2019)

Arthritis and the Rheumatic Diseases
Publicado: (1952)

Innate Lymphoid Cells Activation and Transcriptomic Changes in Response to Human Dengue Infection
por: Poonpanichakul, Tiraput, et al.
Publicado: (2021)

Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis
por: Koch, Alisa E, et al.
Publicado: (2007)

Motivations for inadequate persistence with disease modifying anti-rheumatic drugs in early rheumatoid arthritis: the patient’s perspective
por: Pascual-Ramos, Virginia, et al.
Publicado: (2013)

Bone mineral density changes during treatment of rheumatoid arthritis with disease-modifying-anti-rheumatic drugs
por: Heidari, Behzad, et al.
Publicado: (2012)

Gene expression of Interleukin-18 in rheumatoid arthritis patients on disease modifying anti-rheumatic drug therapy
por: Khalid, Sabeen, et al.
Publicado: (2019)

Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs
por: Abuhelwa, Ahmad Y., et al.
Publicado: (2020)

Molecular Changes in the Adipose Tissue Induced by Rheumatoid Arthritis: Effects of Disease-Modifying Anti-Rheumatic Drugs
por: Arias de la Rosa, Iván, et al.
Publicado: (2021)

Effect of glucocorticoids combined with disease modifying anti-rheumatic drugs on the improvement of symptoms in patients with rheumatoid arthritis
por: Si, Lulu, et al.
Publicado: (2022)

Advances in the implications of the gut microbiota on the treatment efficacy of disease-modifying anti-rheumatic drugs in rheumatoid arthritis
por: Fan, Junyu, et al.
Publicado: (2023)

Cataphoresis in the Treatment of Gout, Rheumatism, and Rheumatoid Arthritis
por: Begg, Charles
Publicado: (1902)

The Differential Diagnosis of Gout, Rheumatism, and Rheumatoid Arthritis
por: Luff, Arthur P.
Publicado: (1900)

DGEMRIC in the Assessment of Pre-Morphological Cartilage Degeneration in Rheumatic Disease: Rheumatoid Arthritis vs. Psoriatic Arthritis
por: Abrar, Daniel B., et al.
Publicado: (2021)

Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs
por: Tawaratsumida, Hiroki, et al.
Publicado: (2017)

Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
por: Birkner, Benjamin, et al.
Publicado: (2020)

Outcomes with Biological Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) in Older Patients Treated for Rheumatoid Arthritis
por: Akter, Ripa, et al.
Publicado: (2020)

Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab
por: Vastesaeger, Nathan, et al.
Publicado: (2016)

Regulatory and other rheumatoid factors in rheumatoid arthritis patients with active disease or in remission
por: Beduleva, Liubov, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7f868mgvmvjk5s36ucauqhi7i8